Protalix BioTherapeutics (PLX) Inventory (2010 - 2026)

Protalix BioTherapeutics' Inventory history runs 17 years deep, the most recent figure standing at $30.5 million for Q1 2026.

• On a quarterly basis, Inventory rose 56.23% year-over-year to $30.5 million in Q1 2026; TTM through Mar 2026 was $30.5 million, a 56.23% increase from a year earlier, with the FY2025 full-year figure at $25.7 million, up 21.12% from the prior year.
• Inventory improved to $30.5 million in Q1 2026 per PLX's latest filing, from $25.7 million in the prior quarter.
• Across five years, Inventory topped out at $30.5 million in Q1 2026 and bottomed at $14.6 million in Q3 2022.
• The 5-year median for Inventory is $20.3 million (2023), against an average of $20.3 million.
• Across the five-year window, Inventory slipped 20.31% in 2024 and jumped 56.23% in 2026, its largest moves.
• Year by year, Inventory stood at $16.8 million in 2022, then climbed by 13.34% to $19.0 million in 2023, then climbed by 11.54% to $21.2 million in 2024, then climbed by 21.12% to $25.7 million in 2025, then gained by 18.44% to $30.5 million in 2026.
• Per Business Quant, the three latest PLX Inventory figures stand at $30.5 million (Q1 2026), $25.7 million (Q4 2025), and $21.3 million (Q3 2025).